NEWTON, Mass.--(BUSINESS WIRE)--Jan. 13, 2006-- Company Continues to Strengthen Intellectual Property Portfolio-- Receives New U.S. Patent for the Delivery of a Therapeutic Agent to Reduce Toxicity. Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds to enhance the treatment of serious diseases, today announced the addition of Anatole Klyosov, Ph.D., D.Sc., to the senior management team as Chief Scientist. Dr. Klyosov, who provided scientific services on a consulting basis, is a co-founder of the Company and co-developer of DAVANAT(R), a proprietary polysaccharide in a CARBOSOME(TM) formation that target delivers chemotherapy drugs to protein receptors (lectins) found on cancer cells.